DENVER HEALTH.

Same Day Identification of Enterobacteriaceae Directly from Urine Samples

Kon, SE¹, Giddins S², Yushkevich I², Fuchs M³, Irwin A², Metzger S³, Price CS^{1,2}

Contact: Shelley.Kon@cuanschutz.edu

No Conflicts of Interest to Disclose



University of Colorado Hospital. 2. Denver Health and Hospital, University of Colorado School of Medicine

3. Accelerate Diagnostics

Supported by NIH RO1AI116993

Poster 20702180

Amended Abstract

Background: Urinary tract infections (UTIs) are one of the most common infections, associated with 10.5 million outpatient visits annually. Fast and accurate identification (ID) of bacteria causing a UTI would allow for immediate targeted therapy, as opposed to conventional methods which take one to three days. The Accelerate Pheno® system (ACC, Accelerate Diagnostics Inc., Tucson, AZ, USA) provides microbial ID and susceptibility (AST) from positive blood cultures. Our objective was to determine ACC's potential to quickly ID bacterial pathogens directly from urine

Materials/methods: Remnant urine samples with >100K colony forming units (CFU)/mL of gram-negative bacteria as determined by quantitative plating were obtained from the clinical lab. 1.5ml of urine was loaded onto the Accelerate PhenoPrep™ module, then into the ACC for analysis using a custom designed assay which detects the presence of bacteria and employs an Enterobacteriaceae family specific FISH probe. The results were compared to standard of care ID results.

Results: There were 10 E. coli and 1 C. koseri among the eleven samples tested. Baseline concentration of samples immediately prior to testing ranged from 2.5 x 10⁶ to 1.08 x 10¹⁰ CFU/mL (average 4.19 x 10⁹). After specimen processing, average concentration was 2.14 x 109 CFU/mL and average recovery was 42.83%. ACC detected bacteria and identified it as Enterobacteriaceae in 11/11 samples (100%). Average sample prep time was 55 min. Average time to Enterobacteriaceae ID was 8.6 hrs. Average total time to ID, including specimen processing, was 9.5 hrs.


Conclusions: ACC identified Enterobacteriaceae directly from remnant urine specimens in an average of 9.5 hours, approximately 24 to 48 hours faster than conventional methods. ACC was able to be adapted for use in urine samples.

Background

We chose to focus on urine specimens because of the clinical impact of **Urinary Tract Infections (UTIs):**

- 10.5 million outpatient visits for UTIs in the year 2000
- A very common reason for outpatient antibiotic prescriptions
- Cost 3.5 billion US dollars annually
- Current methods take 1 to 3 days to provide a microbiologic diagnosis
- The Accelerate Pheno® system (ACC, Accelerate Diagnostics Inc., Tucson, AZ, USA) can provide microbial ID and susceptibility (AST) from positive blood cultures.

Hypothesis: The ACC can quickly ID bacterial pathogens directly from urine



processing (mean

CFU/ml)

 2.14×10^9

Concentration of

Samples (mean

CFU/ml)

 4.19×10^9

specimen processing

42.83%.

concentration/baseline

concentration in CFU/ml)

Results

	Bacteria Detected?	Enterobacteriaceae Detected?	Concordance with clinical lab
Total n=11	11	11	100%
E.coli n=10	10	10	100%
C. koseri n=1	1	1	100%

Sample prep time (mean)	Time to Enterobacteriaceae ID (mean)	Total time to ID (mean)	Conventional Methods (mean)	Time saved (mean)
55 min	8.6 hrs	9.5 hrs	24-48 hrs	<mark>26.5 hrs</mark>

Limitations

- Remnant samples were used for testing
- Small sample size
- Was difficult to obtain other species due to abundance of E.coli in clinical samples available

Conclusions

- ACC identified Enterobacteriaceae directly from remnant urine specimens in an average of 9.5 hours, approximately 24 to 48 hours faster than conventional methods.
- ACC was able to be adapted for use in urine samples.
- Future directions include improving the assay to identify bacteria to the species level and adding AST testing.
- This shows promise in providing fast actionable UTI diagnosis, allowing for tailored antibiotic therapy.

*The information in this poster concerns a use that has not been approved or cleared by the Food and Drug Administration. Research reported in this abstract and poster was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health under award number RO1Al116993. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health